In a review, researchers discussed the value of combining immunotherapy, targeted therapy, and chemotherapy to improve treatment for double hit lymphoma.
This data analysis examined the effect of alcohol consumption on the risk of lethal prostate cancer in men at risk of the disease, and those who developed nonmetastatic prostate cancer during follow-up.
Improvements to PFS and “clinically meaningful reductions in daily corticosteroid use” were said to be linked to the addition of bevacizumab in glioblastoma.
With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma.
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.
One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results.
Updated guidelines advised against performing cytoreductive nephrectomy in poor-risk patients.
New research has linked microsatellite instability and the number of insertion/deletion mutations present in a tumor to clinical response to checkpoint inhibition.
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
Prospective studies on talc and cancer are necessary to fully form our collective understanding of talc’s risks.
A universal cancer gene therapy from the early 2000s is headed into phase 2 trials, in light of renewed interest and outlier patients who are still alive at 10 years later.
Research suggests that ibrutinib may have the ability to alter the phenotype of a final CAR-T cell product.
Despite a challenging toxicity profile, high dose interleukin-2 (HD IL-2), one of the earliest-approved immunotherapies for metastatic renal cell carcinoma still has a role in treating selected patients, a new registry analysis shows.
An Italian trial reported fewer deaths with annual or biennial low-dose CT lung screening—and an active surveillance approach reduced overdiagnosis.
Pembrolizumab improved PFS in this high-risk patient population, but a randomized controlled trial is warranted.